Mirova Reduces Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Mirova cut its holdings in Edwards Lifesciences Co. (NYSE:EW) by 82.2% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,143 shares of the medical research company’s stock after selling 5,296 shares during the quarter. Mirova’s holdings in Edwards Lifesciences were worth $85,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Crowley Wealth Management Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $26,000. Millstone Evans Group LLC acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth $30,000. Roble Belko & Company Inc purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $46,000. Finally, Catalyst Capital Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $54,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the sale, the director now owns 60,372 shares in the company, valued at $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,189,770.56. The trade was a 16.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,853 shares of company stock valued at $5,163,062 in the last three months. Corporate insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on EW shares. Canaccord Genuity Group raised their price target on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. Wolfe Research downgraded Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Morgan Stanley lifted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Finally, Evercore ISI dropped their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $78.55.

Edwards Lifesciences Stock Up 0.5 %

Shares of NYSE EW opened at $71.56 on Friday. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25. The stock has a fifty day moving average price of $71.31 and a 200 day moving average price of $70.88. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market cap of $42.07 billion, a P/E ratio of 10.27, a P/E/G ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Research analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.